TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
Healthcare
$1.36 +6.37%
+$0.14 today
- Market cap
- $89.43M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
52W Low $0.41High $3.90
Volume 0.20M
Average 0.85M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$31.80M
FY 2025 · Annual
Net Income
-$30.06M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 60K | 60K | 55K | 0 | 0 |
| Gross Profit | (60K) | (60K) | (55K) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 15.17M | 9.31M | 2.66M | 13.34M | 20.53M |
| Selling, General & Admin | 7.45M | 5.43M | 5.73M | 3.87M | 7.58M |
| Operating Expenses | 22.62M | 14.74M | 8.4M | 17.65M | 31.8M |
| Depreciation & Amortization | 60K | 60K | 55K | 116.71K | 71.27K |
| EBITDA | (21.97M) | (14.59M) | (8.27M) | (17.43M) | (29.36M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (22.68M) | (14.8M) | (8.45M) | (17.65M) | (31.8M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 57.35K | 89.67K | 361.63K | 136.23K |
| Interest Expense | 629.29K | 0 | 18.69K | 4.14M | 625.28K |
| Other Income / Expenses | 21K | 147K | 131K | (4.03M) | 1.74M |
| Income Before Tax | (22.66M) | (14.65M) | (8.32M) | (21.68M) | (30.06M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (22.66M) | (14.65M) | (8.32M) | (21.68M) | (30.06M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (903.04) | (324.48) | (11.29) | (1.21) | (0.63) |
| EPS (Diluted) | (903.04) | (324.48) | (11.29) | (1.21) | (0.63) |
| 27.83K | 46.29K | 752.91K | 18.66M | 47.93M | |
| 27.83K | 46.29K | 752.91K | 18.66M | 47.93M |
HURA Earnings Waterfall · TTM
NASDAQ:HURA · Revenue to Net Income
Key Ratios
EPS$-0.61
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-3.0
P/S Ratio0.0
Analysis
$0 of revenue converted into -$30.9M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.61, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| 8-K | Current report | Oct 16, 2026 | |
| 8-K | Current report | Sep 24, 2026 |
How much revenue does HURA generate?
TuHURA Biosciences, Inc. (HURA) reported $0.00 of revenue in fiscal 2025.
Is HURA profitable?
TuHURA Biosciences, Inc. (HURA) reported -$30.06M of net income.
Continue the stock analysis
Jump to another research area for this company.